Literature DB >> 21301825

Innovative study design for paediatric clinical trials.

Paola Baiardi1, Carlo Giaquinto, Silvia Girotto, Cristina Manfredi, Adriana Ceci.   

Abstract

PURPOSE: Despite representing a fundamental step towards the efficacious and safe utilisation of drugs in the paediatric population, the conduct of clinical trials in children poses several problems. Methodological issues and ethical concerns represent the major obstacles that have traditionally limited paediatric research. The randomised clinical trial, mainstay of clinical studies to assess the effects of any therapeutic intervention, shows some weaknesses that make it scarcely applicable to the paediatric population. Alternative and innovative approaches to clinical trial design in small populations have been developed in the last few decades with the aim of overcoming the limits related to small samples and to the acceptability of the trial.
METHODS: This systematic review describes a variety of alternative designs to assess efficacy and safety in the paediatric population, including their applicability, advantages, disadvantages and real case examples. Approaches include sequential and adaptive designs, Bayesian methods and other innovative approaches.
RESULTS: By limiting the sample size and increasing acceptability, these methods may rationally limit the amount of experimentation in children to what is achievable, necessary and ethical
CONCLUSION: Thanks to their features, these methods represent a reliable way of ultimately improving paediatric care.

Entities:  

Mesh:

Year:  2011        PMID: 21301825     DOI: 10.1007/s00228-011-0990-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Ethics and practice: alternative designs for phase III randomized clinical trials.

Authors:  C R Palmer; W F Rosenberger
Journal:  Control Clin Trials       Date:  1999-04

2.  The randomized placebo-phase design for clinical trials.

Authors:  B Feldman; E Wang; A Willan; J P Szalai
Journal:  J Clin Epidemiol       Date:  2001-06       Impact factor: 6.437

3.  Ethics and evidence in clinical trials.

Authors:  Steven N Goodman
Journal:  Clin Trials       Date:  2005       Impact factor: 2.486

4.  A three-stage clinical trial design for rare disorders.

Authors:  V E Honkanen; A F Siegel; J P Szalai; V Berger; B M Feldman; J N Siegel
Journal:  Stat Med       Date:  2001-10-30       Impact factor: 2.373

5.  A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barré syndrome.

Authors:  Steven N Goodman; John T Sladky
Journal:  Clin Trials       Date:  2005       Impact factor: 2.486

6.  Vigabatrin withdrawal randomized study in children.

Authors:  C Chiron; O Dulac; L Gram
Journal:  Epilepsy Res       Date:  1996-11       Impact factor: 3.045

7.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

8.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Authors:  Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

Review 9.  Antiepileptic drug development in children: considerations for a revisited strategy.

Authors:  Catherine Chiron; Olivier Dulac; Gerard Pons
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Adaptive design methods in clinical trials - a review.

Authors:  Shein-Chung Chow; Mark Chang
Journal:  Orphanet J Rare Dis       Date:  2008-05-02       Impact factor: 4.123

View more
  14 in total

1.  Peritoneal dialysis does not adversely affect kidney function recovery after congenital heart surgery.

Authors:  Alyssa A Riley; John L Jefferies; David P Nelson; Michael R Bennett; Joshua J Blinder; Qing Ma; Prasad Devarajan; Stuart L Goldstein
Journal:  Int J Artif Organs       Date:  2014-01-20       Impact factor: 1.595

Review 2.  Paediatric pharmacokinetics: key considerations.

Authors:  Hannah Katharine Batchelor; John Francis Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 3.  Sequential analysis in neonatal research-systematic review.

Authors:  Sebastiano A G Lava; Valéry Elie; Phuong Thi Viet Ha; Evelyne Jacqz-Aigrain
Journal:  Eur J Pediatr       Date:  2018-02-16       Impact factor: 3.183

4.  Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.

Authors:  Lesley M Arnold; Lucinda Bateman; Robert H Palmer; Yuhua Lin
Journal:  Pediatr Rheumatol Online J       Date:  2015-06-26       Impact factor: 3.054

5.  Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study.

Authors:  Lesley M Arnold; Kenneth N Schikler; Lucinda Bateman; Tahira Khan; Lynne Pauer; Pritha Bhadra-Brown; Andrew Clair; Marci L Chew; Joseph Scavone
Journal:  Pediatr Rheumatol Online J       Date:  2016-07-30       Impact factor: 3.054

6.  Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches.

Authors:  G Smania; P Baiardi; A Ceci; P Magni; M Cella
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-06-01

Review 7.  Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations.

Authors:  Martina Penazzato; Devasena Gnanashanmugam; Pablo Rojo; Marc Lallemant; Linda L Lewis; Francesca Rocchi; Agnes Saint Raymond; Nathan Ford; Rohan Hazra; Carlo Giaquinto; Yodit Belew; Diana M Gibb; Elaine J Abrams
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

8.  Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group.

Authors:  Athimalaipet V Ramanan; Neena Modi; Saskia N de Wildt
Journal:  Pediatr Res       Date:  2021-06-07       Impact factor: 3.953

9.  Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines.

Authors:  L Ruggieri; V Giannuzzi; P Baiardi; F Bonifazi; E H Davies; C Giaquinto; D Bonifazi; M Felisi; C Chiron; R Pressler; H Rabe; M J Whitaker; A Neubert; E Jacqz-Aigrain; I Eichler; M A Turner; A Ceci
Journal:  Eur J Pediatr       Date:  2014-09-23       Impact factor: 3.183

10.  Challenges in conducting paediatric trials with off-patent drugs.

Authors:  S S Haslund-Krog; I M Jorgensen; T B Henriksen; K Dalhoff; N M Debes; J van den Anker; H Holst
Journal:  Contemp Clin Trials Commun       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.